Clinical Trials Logo

Post Transplant Diabetes Mellitus clinical trials

View clinical trials related to Post Transplant Diabetes Mellitus.

Filter by:
  • None
  • Page 1

NCT ID: NCT02591849 Completed - Clinical trials for Post-transplant Diabetes Mellitus

GLP-1 Effects on Insulin and Glucagon in PTDM

Start date: October 2014
Phase: N/A
Study type: Interventional

Post-transplantation diabetes mellitus (PTDM) develops in 10-15 % of all renal transplant recipients within 10 weeks after transplantation, and has been associated with increased risk of cardiovascular disease and impaired patient survival. PTDM is primarily believed to be a variant of type 2 diabetes mellitus (T2DM), but the pathophysiology underlying the impaired glucose metabolism in renal transplant recipients with PTDM is unclear and some aspects are still poorly investigated. Hyperglycemic clamp investigations with concomitant infusion of glucagon-like peptide-1 (GLP-1) are warranted for a thorough characterization of the α-cell and β-cell function. The primary objective of the present study is to investigate whether hyperglucagonemia is present in renal transplant recipients with PTDM. Furthermore, the investigators aim to examine the insulinotropic and glucagon suppressive effects of GLP-1 (compared to placebo) in PTDM patients during fasting glycemia and during hyperglycemic conditions (hyperglycemic clamp), respectively.

NCT ID: NCT02558452 Not yet recruiting - Quality of Life Clinical Trials

European Transplant Registry of Senior Renal Transplant Recipients on Advagraf

SENIOR
Start date: December 2016
Phase: N/A
Study type: Observational [Patient Registry]

SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate long term outcomes on an observational basis.

NCT ID: NCT01092806 Completed - Clinical trials for Post Transplant Diabetes Mellitus

Insulin Secretion and Advagraf

ADVA-09
Start date: October 2009
Phase: Phase 4
Study type: Interventional

One of the main side-effects of tacrolimus in solid organ transplanted patients is post transplant diabetes mellitus (PTDM). It is not known if different pharmacokinetic properties influence the risk of developing PTDM. It is possible that it either is high peak concentrations of high overall systemic exponation that is responsible for the effect on insulin secretion. With the new slow-release formulation of tacrolimus (Advagraf) a different pharmacokinetic profile is introduced to patients and it is of interest to investigate if this affects insulin secretion and insulin sensitivity of patients. Hypothesis: The pharmacokinetic profile of tacrolimus affects the insulin secretion in renal transplant recipients.